Plain English Summary
An FDA-approved melanocortin-4 receptor agonist specifically indicated for rare genetic obesity conditions (POMC, PCSK1, and LEPR deficiencies). Represents a new class of precision obesity medicine.
What People Use It For
Realistic Expectations
Best Case
Significant weight loss (up to 25% in eligible patients) with improved quality of life.
Common Outcome
Meaningful weight reduction in genetically eligible patients; ineffective in others.
Low / No Response
No effect in patients without the relevant genetic deficiency.
Side Effects & Risks
Common Side Effects
Warnings
- Approved only for specific rare genetic obesity conditions — NOT general obesity
- Hyperpigmentation is common and can be permanent
- Requires genetic testing to confirm eligibility
Who This Is Not For
People without confirmed MC4R pathway genetic defects. Not a general weight loss drug.
Commonly Confused With
Timeline of Expected Changes
Clinical effects demonstrated over 52-week trial periods.
Researchers also explore
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even stronger weight loss results than semaglutide in clinical trials. It targets two hormone pathways instead of one, making it potentially more effective for both weight loss and blood sugar control.
GIP (Glucose-dependent Insulinotropic Polypeptide)
GIP is an endogenous incretin hormone released from the gut after nutrient intake. It plays a critical role in glucose metabolism by stimulating insulin secretion in a glucose-dependent manner. While historically studied for its insulinotropic effects, modern research focuses on its systemic roles in adipose tissue, bone remodeling, and the central nervous system, particularly when combined with GLP-1 for metabolic therapies.
Glucose-dependent insulinotropic polypeptide (GIP)
GIP is an incretin hormone secreted by the intestine that plays a key role in glucose metabolism and energy homeostasis. While traditionally recognized for its role in stimulating insulin secretion in response to nutrient intake, recent research highlights its involvement in lipid metabolism, bone health, and neurological function. It is currently a focal point of therapeutic development in combination with GLP-1 agonists for treating obesity and metabolic disease.
Researcher Sentiment
No votes yet — be the first
Educational Content Only
This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.